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Summary
Background The aim of this study was to analyze the
impact of gender on tumor stage, overall and can-
cer-specific mortality of upper urinary tract urothe-
lial cancer (UTUC) in a population-based, nationwide
analysis.
Methods All Austrian patients with UTUC diagnosed
between 1983 and 2010 were included in this study.
Overall mortality was estimated by the Kaplan-Meier
method. Cancer-specific (UTUC) mortality was esti-
mated by cumulative incidence with mortality due to
other causes as a competing risk. The effect of age
was adjusted in a descriptive as well as a statistical
inferential way.
Results This study included 2066 patients (men n =
1169, mean age 68.3 ±11.5 years, women n = 897,
72.6 ±10.4 years). Tumor stage distribution was as
follows: pT1: men n = 411, women n = 268, pT2: men
n = 263, women n = 187, pT3: men n = 382, women
n = 328 and pT4: men n = 113, women n = 114. The
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male:female ratio continuously declined from 1.5 for
pT1 tumors to 1.4 for pT2 tumors, 1.2 for pT3 tumors
and 1.0 for pT4-tumors. In the entire cohort the 5-year
cumulative overall mortality was 57% for women ver-
sus 50% for men (p = 0.0002). For pT1 (women 33%,
men 31%) and pT2 stage tumors (women 45%, men
45%) the 5-year overall mortality was comparable be-
tween both sexes. In pT3 (women 68%, men 62%)
and pT4 (women 95%, men 87%) tumors women had
a higher overall mortality rate. The 5-year cancer-spe-
cific mortality (CSM) of the entire cohort was 12% for
women and 10% for men (p = 0.067): pT1 women 5%
men 3%, pT2 women 9% men 10%, pT3 women 14%
men 11% and pT4 women 29% men 27%.
Conclusions In this population-based nationwide
analysis, sex differences were notable for UTUC.
Women tended to have more advanced tumor stages
at diagnosis and a higher overall and cancer-specific
mortality in advanced tumor stages.
Keywords Urothelial carcinoma · Upper urinary tract ·
Sex · Radical nephroureterectomy · Tumor stage
Introduction
Upper urinary tract urothelial carcinoma (UTUC) is
a rare urological malignancy accounting for approx-
imately 5–6% of all urothelial tumors with an inci-
dence of 0.7 per 100,000 person-years [1]. Despite the
increased detection of earlier stage tumors resulting
from the recent improvements in imaging and endo-
scopic techniques, UTUC remains an aggressive dis-
ease with high recurrence and progression rates [1, 2].
Prognostic predictors of UTUC can be grossly di-
vided into clinical, demographic and pathological fac-
tors. Demographic factors involve age, obesity, per-







togender and tumor stage
Overall Number (n) Age (years, mean ± SD) Follow-up median estimated value in years (95% CI)
Women total 897 72.6 ± 10.4 14.5 (13.2–15.8)
Men total 1169 68.3 ± 11.5 13.4 (12.3–14.9)
pT1 female 268 72 ± 11.6 15.4 (13.9–17.1)
pT2 female 187 71.7 ± 10.7 15.6 (12.5–20.8)
pT3 female 328 73.4 ± 9.4 11.6 (10.2–14.6)
pT4 female 114 73.0 ± 9.7 13.7 (3.2–22.5)
pT1 male 411 66.7 ± 11.6 12.9 (11.6–15.5)
pT2 male 263 68.6 ± 11.7 16.2 (14.7–18.9)
pT3 male 382 69.1 ± 11.1 11.3 (10.3–14.4)
pT4 male 113 70.4 ± 11.3 11.4 (3.6–13.5)
pT1–pT4 tumor stage according to the AJCC/UICC TEM classification
formance status, smoking and race [1]. Pathological
factors include tumor stage, grade, concomitant car-
cinoma in situ, lymph node invasion, tumor architec-
ture and lymphovascular invasion [1, 2].
The impact of gender on the incidence and progno-
sis of patients with UTUC is still poorly investigated.
Comparable to the situation for bladder cancer, the
role of gender for UTUC is intensively discussed. The
occurrence of UTUC is 2–3 times more common in
men and sex differences relating to clinical and patho-
logical characteristics have been reported but with
conflicting findings [3, 4]. The vast majority of pre-
vious studies on this topic are hampered by relatively
small sample sizes and/or potential selection bias of
data reported by tertiary referral centers.
We therefore aimed to assess the impact of sex on
(i) tumor stage of UTUC at diagnosis and (ii) on overall
and cancer specific mortality in a population-based,
nationwide analysis. To this end we linked the na-
tional cancer registry to the national death statistics.
For decades, Austria (total population 8.4 million) has
had an equal access healthcare system with compul-
sory state insurance and a national cancer registry.
Material and methods
Data on cancer incidence were obtained from the Aus-
trian National Cancer Registry. All patients with UTUC
with tumor stages pT1, pT2, pT3 and pT4 diagnosed
between 1983 until 2010 were followed up. The in-
formation collected included the following variables:
date of birth, sex, date of diagnosis, stage, site and his-
tological type of the tumor according to the Standard
International Classification of Diseases for Oncology
(ICD-O-3).
The cancer incidence database is regularly matched
with official death certificates by Statistics Austria.
Statistics related to the causes of death (Statistics
Austria) were used for passive follow-up and informa-
tion related to the date of death and cause of death
was obtained. Complete data were recoded into ICD-
10 and included incidence as well as survival data
of codes C65 and C66 (malignant neoplasm of re-
nal pelvis and malignant neoplasm of ureter). The
overall mortality was estimated by the Kaplan-Meier
method, UTUC-specific mortality was estimated by
cumulative incidence using the %CIF macro provided
by SAS (SAS Institute, Cary, NC) with mortality due
to other causes as a competing risk. The SAS macro
allows estimation of cumulative incidence functions
with competing risks and provides a comparison of
cumulative incidence functions by the Gray test [5].
Furthermore, the effect of sex was adjusted by age at
diagnosis by means of a Cox as well as a Fine-Gray
regression model using the phreg in SAS. For descrip-
tive purposes only, age at diagnosis was grouped into
<70 years and >70 years and cumulative incidence was
calculated for each group. Corresponding p-values are
explorative in the sense that no prespecified hypothe-
ses were set up in advance of the study and no adjust-
ments for multiple tests were applied. Median follow-
up times were calculated by the reverse Kaplan-Meier
method.
Tumors were staged according to the 2002 Amer-
ican Joint Committee on Cancer and International
Union against Cancer (AJCC/UICC) TNM classifica-
tion [6]. Tumor grade was assessed according to the
1998 World Health Organization and International




Between 1983 and 2010 a total of 2066 patients in-
cluding 1169 men (56.6%) and 897 women (43.4%)
with UTUC were identified and included in this study
(Table 1). The median follow-up of the male cohort
was 13.4 years (95% confidence interval CI 12.3–14.9
years) and of the female cohort 14.5 years (95%CI
13.2–15.9 years). The mean age of the entire cohort
was 70.1 ± 11.2 years (women 72.6 ± 10.4 years, men
68.3 ± 11.4 years, p = 0.0017). This sex-specific age dif-
ference at diagnosis was demonstrable for all tumor
stages (Table 1). The tumor stage distribution within
sex was as follows: pT1 men n = 411 (35.2%), women
n = 268 (28.9%), pT2 men n = 263 (22.5%), women
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Fig. 1 Cumulativeoverall andcancer specificmortality in total
studycohort
Fig. 2 Cumulativeoverallmortality dependingonsex and tu-
mor stage
n = 187 (20.8%), pT3 men n = 382 (32.7%), women n =
328 (36.6%) and pT4 men n = 113 (9.6%), women n =
114 (12.7%). The male: female ratio continuously de-
clined from 1.5 for pT1 tumors to 1.4 for pT2 tumors,
1.2 for pT3 tumors and 1.0 for pT4 tumors.
In the male cohort there was an association be-
tween age and tumor stage, i. e. advanced stages in
higher age groups: pT1 66.7 ± 11.6 years (mean ± SD),
pT2 68.6 ± 11.7 years, pT3 69.2 ± 11.1 years and pT4
70.4 ± 11.3 years. This age trend, however, was not
present in women: pT1 72.0 ± 11.6 years, pT2 71.7 ±
10.7 years, pT3 73.3 ± 9.4 years and pT4 73.0 ± 9.8
years.
Cumulative overall mortality
The 5-year cumulative overall mortality was 57%
(95%CI: 53–59%) for women versus 50% (47–53%)
for men (p = 0.0002) (Fig. 1, Table 2). For pT1 tu-
mors women 33% (27–39%), men 31% (27–36%)
and pT2 tumors women 45% (38–52%), men 45%
(39–51%) the 5-year overall mortality rates were com-
Fig. 3 Cumulativeoverallmortality dependingonsex and tu-




parable (Fig. 2). In pT3 and pT4-tumors, however,
women showed a higher cumulative mortality, in pT3
for women was 68% (62–73%), for men was 62%
(56–66%) and for pT4 women 95% (89–98%) and men
87% (79–92%). To limit the impact of the age differ-
ence at diagnosis (see Table 1) we grouped patients
into a <70 years (men 59.5 ± 8.5 years, women 61.5 ±
7.4 years) and a >70 years cohort (men 77.7 ± 5.2 years,
women 78.9 ± 5.4 years) and performed a analysis by
stage (Fig. 3). In principal, these data confirm those
presented in Fig. 2.
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Table 2 Overallmortalityaccording tosexandtumorstage
Tumor stage Alive (n) Deceased (n) Total
pT1 female 104 164 268
pT1 male 172 239 411
pT2 female 54 133 187
pT2 male 79 184 263
pT3 female 65 263 328
pT3 male 98 284 382
pT4 female 4 110 114
pT4 male 13 100 113
Total 589 1477 2066
Observed estimated differences between both sexes
within tumor stages were not significant as assessed
by a Cox and a Fine-Gray regression model for pT2
(p = 0.67) and pT3 tumors (p = 0.33). For pT4 tumors,
the sex difference was significant (p = 0.044) and for
pT1 tumors the difference was on the border of sig-
nificance (p = 0.06).
Cumulative cancer-specific mortality
The 5-year cancer-specific mortality (CSM) of the en-
tire cohort was 12% for women and 10% for men (p =
0.067) (Fig. 4, Table 3). The 5-year cumulative cancer
and specific sex mortality was as follows: pT1 tumors
5% (2–8%) for women versus 3% (1–5%) formen, pT2
tumors 9% (5–10%) for women versus 10% (6–10%)
for men, pT3 tumors 14% (10–18%) for women versus
11% (8–15%) for men and pT4 tumors 29% (21–38%)
for women versus 27% (19–35%) for men. Fig. 5
presents CSM rates in the two age cohorts (<70 years
vs. ≥70 years) thus largely confirming the data of the
overall group (see Fig. 4). Observed estimated differ-
ences between groups within tumor stages were not
significant as assessed by a Cox and a Fine-Gray re-
gression model because of low numbers of events and
subsequently low power of the statistical tests.
Discussion
This large-scale population-based analysis of UTUC
has two major findings: (1) women presented with
more advanced tumor stages and (2) women tended
to have a higher overall and cancer-specific mortality
in advanced tumor stages.
Prior discussion, some advantages and limitations
of the current study design need to be mentioned.
Strengths are (i) the population-based approach,
(ii) the large cohort, (iii) the fact that for decades
Austria has had an equal access healthcare system
and (iv) that there is an almost complete follow-up
(unless the patient left Austria) due to matching the
cancer incidence database to the national mortality
statistics by Statistic Austria. The major limitation is
the lack of any clinical information including primary
Table 3 Cancer-specificmortality according to tumor
stageandsex
Tumor stage Alive Cancer deaths Other deaths Total
pT1 female 104 13 151 268
pT1 male 172 13 226 411
pT2 female 54 17 116 187
pT2 male 79 26 158 263
pT3 female 65 46 217 328
pT3 male 98 45 239 382
pT4 female 4 34 76 114
pT4 male 13 31 69 113
Total 589 225 1252 2066
and secondary treatment; however, to be included
to the Austrian Cancer registry a histological diagno-
sis is mandatory. It is the rare exception in Austria
that a positive biopsy of UTUC is not followed by
a nephroureterectomy (N/U); however, we have no
information on the type of N/U, if a bladder cuff has
been excised or the extent of lymphadenectomy. This
population-based series with 2066 patients detected
a fairly strong sex-specific tumor shift towards more
advanced stages in women: the male to female ratio
continuously declined from 1.5 for pT1-tumors to 1.4
for pT2 tumors, 1.2 for pT3 tumors and 1.0 for pT4
tumors. This trend, however, has not been uniformly
observed. Shariat et al. [8], for instance, studied 754
patients (68.4% men) undergoing N/U in a multicen-
ter (n = 9) retrospective setting. In this series the
male to female ratio increased from 1.8 for pT1 tu-
mors to 2 for pT2 tumors and from 2.1 for pT3 tumors
to 2.9 for pT4 tumors. In a further N/U series, Fer-
nandez et al. [9] studied 1363 patients (67.6%) men
in a similar multicenter (n = 13) setting. The male to
female ratio was comparable for all T stages (2.1 for
pT1, 2.1 for pT2 and 2 for pT3). Further, smaller sized
surgical series led to contradictory results in this re-
spect [10–13]. Lughezzani et al. [14] studied 4850
patients (59.9% men) who underwent N/U using the
SEER data base. This large-scale population-based se-
ries partly supports our findings as the authors ob-
served a higher proportion of women in pT3 stages
(pT4 stages were not reported) [14]. The reasons for
these discrepant data remain poorly understood. As
pointed out by Lughezzani et al. [14], patient selection
may be a factor as the majority of studies were sur-
gical series from tertiary centers. Furthermore, many
series are hampered by the limited sample size due to
the low incidence of UTUC; however, the two largest,
population-based studies in this respect support this
gender-specific stage shift in UTUC. Our group has
recently reported a similar phenomenon by analysing
27,733 patients with bladder cancer in Austria [15].
It has been postulated that a gender-specific referral
pattern might be a major factor for the stage shift in
women with bladder cancer [16] and one can spec-
ulate that the same also applies for UTUC. It is very
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Fig. 5 Cumulativecancer-specificmortalitydependingonsex
and tumor stage in twoagecohorts (a<70yearsat diagnosis,
b≥70yearsat diagnosis)
likely that there is a lack of immediate diagnostic
work-up of females with microhematuria. Other po-
tential causes may be different carcinogen exposure
and metabolism (e.g. tobacco and chemicals) as well
as reflective of genetic, anatomical, hormonal and
environmental factors. Similar to the situation for
bladder cancer, these data should sensitize the med-
ical community for immediate work-up of women,
e. g. with hematuria.
The second part of the study deals with the impact
of sex on overall and cancer-specific mortality; how-
ever, as in most cancer registry studies using gender
as an independent predictor, there is the shortcoming
that age at diagnosis was consistently more advanced
in women (see Table 1). We have adjusted the effect
of age in a descriptive and a statistical-inferential way.
The statistical analyses, however, were hampered by
the relatively low number of events particularly per
stage group, when comparing the results, e. g. to a
similar analysis of our group of bladder cancer pa-
tients using a 10-fold larger data base [15].
Similar to the issue of a gender-specific stage shift,
the impact of female gender on the outcome of UTUC
is a controversial matter. In our series, women had
a higher overall (0.56 vs. 0.50, p = 0.0002) and can-
cer-specific mortality (0.12 vs. 0.10, p = 0.067). With
respect to CSM our data are in line with the series of
Lughezzani et al. [14] who also observed a higher CSM
in women (p = 0.03). The 5-year CSM rate in females
was 16.9% vs. 14.8% in males in the SEER-database;
these figures are remarkable similar to our series [14].
In stage-specific analyses, women had a higher CSM
for pT2 and pT3 tumors [14]; however, in contrast to
our series, men had a higher overall mortality in the
advanced stages. Shariat et al. [8] reported on no
gender difference regarding cancer-specific survival in
a series of 754 patients who underwent N/U. Similar
data were reported by Choo et al. [10]. These negative
data are contrasted by Sikic et al. [11] who studied 268
patients and Liu et al. [12] who studied 285 patients.
Both studies reported that female sex was an age-de-
pendent prognostic factor for cancer specific survival
for patients with UTUC treated with N/U.
Conclusion
According to our knowledge, this is the largest popu-
lation-based and nationwide series on the impact of
gender on tumor stage and outcome of UTUC. Similar
to the situation for bladder cancer, gender differences
were notable for UTUC. Women tended to have more
advanced tumor stages and a higher overall and can-
cer specific mortality in advanced stages. The statisti-
cal analyses were hampered by the rather low number
of events particularly per stage group.
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